Evidence map›Paper›PMID 41275867›Full record

ReviewCancer control : journal of the Moffitt Cancer Center

Mechanisms and Applications of γδ T Cells in Anti-Tumor Immunity.

Yu Zhang, Jiawang Liu, Junwen Yao, Nanhai Yuan, Ruiquan Xu

Abstract readReview
In one paragraph

Review in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yu ZhangDepartment of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.ORCID 0009-0004-3244-6100
Jiawang LiuDepartment of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Junwen YaoDepartment of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Nanhai YuanDepartment of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Ruiquan XuDepartment of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

γδ T cells represent a distinctive subset of immune cells with considerable promise in cancer immunotherapy. They recognize a broad spectrum of tumor-associated antigens via non-major histocompatibility complex (non-MHC) pathways and exert antitumor effects by inducing apoptosis, directly lysing tumor cells, and modulating other immune components. This unique antigen-recognition capacity has spurred extensive efforts to harness γδ T cells for innovative immunotherapeutic applications. Consequently, their use in cancer treatment is gaining increasing traction. Researchers have employed genetic engineering and other strategies to enhance γδ T cell anti-tumor efficacy and have begun evaluating their potential in clinical trials. However, this therapeutic approach faces notable challenges, including interindividual variability in response and risk of adverse effects. Future research should aim to achieve a more comprehensive understanding of the mechanisms of γδ T cells across different tumor types and improve their safety and efficacy in clinical settings. This review synthesizes recent advances in γδ T cell research, examining their roles in tumor recognition, cytotoxicity, immunoregulation, and anti-tumor immunity. It further evaluates preclinical and clinical evidence to assess the therapeutic potential of γδ T cell-based cancer immunotherapies.

Indexed as

ImmunotherapyNeoplasmsReceptors, Antigen, T-Cell, gamma-deltaT-LymphocytesAnimalsHumansReceptors, Antigen, T-Cell, gamma-deltaanti-tumorimmunotherapytumor immunitytumor microenvironmentγδ T cells

Identifiers

PMID41275867
PMCPMC12641087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.